Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Colmegna B, Uboldi S, Frapolli R, Licandro SA, Panini N, Galmarini CM, Badri N, Spanswick VJ, Bingham JP, Kiakos K, Erba E, Hartley JA, D'Incalci M.

Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407. Epub 2015 Dec 3.


Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.

Mellinas-Gomez M, Spanswick VJ, Paredes-Moscosso SR, Robson M, Pedley RB, Thurston DE, Baines SJ, Stell A, Hartley JA.

BMC Vet Res. 2015 Aug 19;11:215. doi: 10.1186/s12917-015-0534-2.


Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.

Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA.

Oncotarget. 2015 Apr 30;6(12):10548-62.


Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining.

Cook R, Zoumpoulidou G, Luczynski MT, Rieger S, Moquet J, Spanswick VJ, Hartley JA, Rothkamm K, Huang PH, Mittnacht S.

Cell Rep. 2015 Mar 31;10(12):2006-18. doi: 10.1016/j.celrep.2015.02.059. Epub 2015 Mar 26.


γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA.

Clin Cancer Res. 2013 Feb 1;19(3):721-30. doi: 10.1158/1078-0432.CCR-12-2529. Epub 2012 Dec 18.


Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser D, Hartley JA.

BMC Cancer. 2012 Sep 28;12:436. doi: 10.1186/1471-2407-12-436.


Measurement of DNA damage in individual cells using the Single Cell Gel Electrophoresis (Comet) assay.

Hartley JM, Spanswick VJ, Hartley JA.

Methods Mol Biol. 2011;731:309-20. doi: 10.1007/978-1-61779-080-5_25.


Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.

Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML.

Clin Cancer Res. 2011 Jun 1;17(11):3794-802. doi: 10.1158/1078-0432.CCR-10-2056. Epub 2011 Feb 23.


Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats.

Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA, Thurston DE, Tomaszewski JE, Ames MM.

Cancer Chemother Pharmacol. 2011 Sep;68(3):777-86. doi: 10.1007/s00280-010-1517-4. Epub 2010 Dec 28.


Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.

Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, James LE, Hartley JA.

Clin Cancer Res. 2010 Oct 1;16(19):4899-905. doi: 10.1158/1078-0432.CCR-10-0832. Epub 2010 Aug 18.


Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Spanswick VJ, Davies S, Hartley JA, Kerr DJ.

Sci Transl Med. 2010 Jul 14;2(40):40ra50. doi: 10.1126/scitranslmed.3000615.


Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay.

Spanswick VJ, Hartley JM, Hartley JA.

Methods Mol Biol. 2010;613:267-82. doi: 10.1007/978-1-60327-418-0_17.


Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.

Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, Cobb M, Gumbrell L, Begent RH, Hartley JA, Jodrell D.

Clin Cancer Res. 2009 Mar 15;15(6):2140-7. doi: 10.1158/1078-0432.CCR-08-1315. Epub 2009 Mar 10.


Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.

Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI, Guichard SM.

Mol Cancer Ther. 2006 Jun;5(6):1602-9.


Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.

Masterson LA, Spanswick VJ, Hartley JA, Begent RH, Howard PW, Thurston DE.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):252-6. Epub 2005 Nov 15.


Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.

Corrie PG, Shaw J, Spanswick VJ, Sehmbi R, Jonson A, Mayer A, Bulusu R, Hartley JA, Cree IA.

Br J Cancer. 2005 Jun 6;92(11):1997-2003.


SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.

Cancer Res. 2004 Sep 15;64(18):6693-9.


Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.

Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA.

Blood. 2002 Jul 1;100(1):224-9.


Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

McHugh PJ, Spanswick VJ, Hartley JA.

Lancet Oncol. 2001 Aug;2(8):483-90. Review.


Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells.

Wickremasinghe RG, Ganeshaguru K, Jones DT, Lindsay C, Spanswick VJ, Hartley JA, Wadhwa M, Thorpe R, Hoffbrand AV, Prentice HG, Mehta AB.

Br J Haematol. 2001 Sep;114(3):608-15.


Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.

Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA.

Clin Cancer Res. 1999 Mar;5(3):507-12.


Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay.

Spanswick VJ, Hartley JM, Ward TH, Hartley JA.

Methods Mol Med. 1999;28:143-54. doi: 10.1385/1-59259-687-8:143.


Pharmacological determinants of the antitumour activity of mitomycin C.

Spanswick VJ, Cummings J, Ritchie AA, Smyth JF.

Biochem Pharmacol. 1998 Dec 1;56(11):1497-503.


Current issues in the enzymology of mitomycin C metabolic activation.

Spanswick VJ, Cummings J, Smyth JF.

Gen Pharmacol. 1998 Oct;31(4):539-44. Review.


Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.

Cummings J, Spanswick VJ, Tomasz M, Smyth JF.

Biochem Pharmacol. 1998 Aug 15;56(4):405-14. Review.


Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.

Cummings J, Spanswick VJ, Gardiner J, Ritchie A, Smyth JF.

Biochem Pharmacol. 1998 Feb 1;55(3):253-60.


The autoxidation of the reduced forms of EO9.

Butler J, Spanswick VJ, Cummings J.

Free Radic Res. 1996 Aug;25(2):141-8.


Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.

Spanswick VJ, Cummings J, Smyth JF.

Biochem Pharmacol. 1996 Jun 28;51(12):1623-30.


Re-evaluation of the molecular pharmacology of mitomycin C.

Cummings J, Spanswick VJ, Smyth JF.

Eur J Cancer. 1995 Nov;31A(12):1928-33. Review. No abstract available.


Supplemental Content

Loading ...
Support Center